Table of Contents
Sidney Riegelman, the Man, His Work and His Impact.- 1. Sidney Riegelman — The Wisconsin Years.- 2. Sidney Riegelman — Friend and Colleague.- 3. Signey Riegelman — The Educator.- 4. Sidney Riegelman — The Scientist.- 5. Sidney Riegelman — His Contributions to Public Policy in Pharmacy and the Pharmaceutical Sciences.- 6. Sidney Riegelman — Contributions at the Clinical Interface.- Biopharmaceutics — Drug Delivery.- 7. Personal Experiences in the Early Days of Biopharmacy and Pharmacokinetics.- 8. Modern Pharmaceutical Dosage Forms.- 9. Specificity of Esterases and Effect of Structure of Prodrug Esters of Acylated Acetaminophen on Hydrolytic Reactivity.- 10. Transdermal Absorption: A Unique Opportunity for Drug Delivery.- 11. Pharmacokinetics and Pharmaceutical Technology.- 12. Bioavailability and Pharmacokinetics in Drug Development.- Pharmacokinetics — Concepts, Theory and Application.- 13. Clearance — Models, Validation and Implications.- 14. Estimation of an Effective Half-Life.- 15. Pharmacokinetic Aspects of Nonlinear Drug-Protein Binding.- 16. Unusual Pharmacokinetics.- Pharmacokinetics and Drug Metabolism.- 17. Assessment and Prediction of In Vivo Oxidative Drug Metabolizing Activity.- 18. Pharmacokinetic and Pharmacological Aspects of Polymorphic Drug Oxidation in Man.- 19. Problems in Correlating In Vitro and In Vivo Studies of Drug Metabolism.- 20. Integral Procedures in Pharmacokinetics and Their Application to the Parameter Determination of Appearing Metabolites.- 21. Pharmacokinetics at the Interface Between Pharmacology and Physiology.- Pharmacokinetics — Drug Dosing and Drug Effects.- 22. Methods for Drug Dosage Individualization: Past, Present and Future.- 23. Treatment of Depression — Pharmacokinetic and Pharmacogenetic Considerations.- 24. Kinetics of Drug Action.- Pharmacokinetics and Biopharmaceutics of Chemotherapeutic and Immunosuppressive Agents.- 25. Cancer Drug Delivery Systems: Macromolecular Prodrugs of Mitomycin C.- 26. Organ Variation in Tissue to Plasma Partition Coefficients of Adriamycin, Daunomycin and Actinomycin-D: Correlation to Tissue DNA Concentrations.- 27. Clinical Pharmacokinetics in the Therapeutic Management of Cancer Patients with Methotrexate and Adriamycin.- 28. The Immunopharmacokinetics of Prednisone/ Prednisolone.- Communications.- 1. The Interpretation of In Vivo Mean Dissolution Time Data.- 2. Application of Statistical Moment Analysis to the Evaluation of Controlled Release Formulations.- 3. Concept of Time-Averaged Total Clearance and Mean Residence Time in Michaelis-Menten Elimination Systems.- 4. A General Method of Optimizing Individual Drug Dosage.- 5. Estimation of Population Pharmacokinetic Parameters with the Computer System NONMEM: Patients Treated with Lidocaine and Mexiletine.- 6. Considerations of Linear Regression with Errors in Both Variables as Applied to Clinical Pharmacokinetics.- 7. Intestinal Drug Metabolism — Presystemic and Systemic Mechanisms and Implications.- 8. Pharmacokinetics of Aspirin: Total and Presystemic Clearance by Rats and Hydrolysis in Blood of Rats and Humans.- 9. Do Plasma Concentrations of Acetaminophen and Its Conjugated Metabolites Reflect Concentrations in Various Tissues?.- 10. Interspecies Variations in Pharmacokinetics: A Perspective.- 11. Nonrenal Elimination, Extensive Renal Tubular Reabsorption and Secretion of Creatinine in Humans and Animals.- 12. Phenobarbital Pharmacokinetics with Particular Emphasis on the Treatment of Overdosed Patients.- 13. Renal Elimination in Alcoholic Cirrhosis.- 14. Altered Disposition of Naproxen by Cirrhotic and by Elderly Individuals.- 15. Drug-Drug Interactions: Protean Manifestations.- 16. Kinetics and Antiarrhythmic Effect of Dihydroquinidine.- 17. Quinidine-N-Oxide: Structure and Pharmacokinetics of a New Quinidine Metabolite.- 18. Phenobarbital Inductions of Quinidine Plasma Protein Binding in Dogs and Its Effect on Quinidine Disposition.- 19. Covalent Binding of Quinidine.- 20. The Use of the Portacaval Transposition Technique to Study Gastrointestinal and Hepatic Metabolism of Propranolol in Dogs.- 21. Stereoselective Disposition and Glucuronidation of Propranolol in Man.- 22. Effect of Renal and Hepatic Insufficiency on the Pharmacokinetics of Betaxolol, a New Adrenergic ß-Blocker.- 23. A Selective HPLC Assay for Simultaneous Quantitation of Fourteen Methylxanthines and Methyluric Acids in Urine.- 24. A Composite View of Theophylline Elimination in Man.- 25. The Influence of Food on the Bioavailability of a Sustained Release Theophylline Formulation.- 26. Pharmacokinetics of the Vasodilators Hydralazine and Endralazine.- 27. Formation of Mono- and Dinitrate Metabolites of Nitroglycerin Following Incubation with Human Blood.- 28. A Pharmacodynamic Model for Thiazinamium in Asthmatic Patients.- 29. Protein Binding Estimates in the Presence of Volume Shifts During Equilibrium Dialysis.- 30. Opiate Pharmacokinetics: In Vivo Receptor Binding and Pharmacological Effects.- 31. Cefoperazone Pharmacokinetics in Healthy Chinese Volunteers.- Appendix and Index.- Sidney Riegelman — Scientific Bibliography.
